Apatinib vs Ramucirumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGFR2 · full Non-Small Cell Lung Cancer pipeline

Apatinib

Marketed by Jiangsu Hengrui Pharmaceuticals under a licence from Advenchen Laboratories

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT02332512 · Phase 3 · status unknown

This is a randomized, placebo-controlled trial with full blinding of participants, care providers, and assessors, using overall survival, a hard clinical endpoint, as its primary measure. Results have not yet been posted, so whether apatinib extended survival compared with placebo is not yet known.

Next expected readout: February 2027 · NCT07031154 (registry estimate)

Reported efficacy

Progression free survival (8 weeks): Primary (PFS): median 4.7 vs 1.9 months, apatinib vs placebo, significantly improved; ORR 12.2% vs 0%; DCR 69% vs 24%. (met)

Result source: NCT01270386

Ramucirumab

Marketed by Eli Lilly

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT01168973 · Phase 3 · completed

This large randomized, double-blind, placebo-controlled trial assigned 628 participants to ramucirumab plus docetaxel and 625 to placebo plus docetaxel, with overall survival as a hard clinical primary endpoint. The published primary analysis met its endpoint: median overall survival 10.5 vs 9.1 months (hazard ratio 0.86, 95% CI 0.75-0.98; p=0.023).

Next expected readout: December 2026 · NCT03909334 (registry estimate)

Reported efficacy

Overall survival (From date of randomization to date of death due to any cause, assessed up to 3 years): Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. (missed)

Result source: NCT05633602

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointApatinibRamucirumab
PFS, median—Not reported4.5 vs 3+1.5 vs placebon 628NCT01168973
15 other results
  • 5.2 vs 4.2 n 76 · Phase 2 · primary NCT01703091
  • 7.2 vs 5.6 n 69 · Phase 2 · primary NCT01160744
  • 5.6 vs 5.6 n 71 · Phase 2 · primary NCT01160744
  • 8.2 n 7 · Phase 2 · primary NCT02730247
  • 4.5 vs 5.2 n 69 · Phase 2 · secondary NCT03971474
  • 1.6 abemaciclib (dose not specified) + 1250 mg/m^2 gemcitabine · n 24 · Phase 1 · secondary NCT02079636
  • 5.5 abemaciclib (dose not specified) + 500 mg/m^2 pemetrexed · n 23 · Phase 1 · secondary NCT02079636
  • 1.9 abemaciclib (dose not specified) + 100, 150, or 200 mg LY3023414 · n 36 · Phase 1 · secondary NCT02079636
  • 4.1 100 or 150 mg abemaciclib + 200 mg pembrolizumab · n 20 · Phase 1 · secondary NCT02079636
  • 4.8 abemaciclib (dose not specified) + 8 or 10 mg/kg ramucirumab on Day 1/8 · n 39 · Phase 1 · secondary NCT02079636
  • 7.8 n 40 · Phase 2 · secondary NCT00735696
  • 1.6 n 16 · Phase 1/2 · secondary NCT02082210
  • 5.4 n 45 · Phase 1/2 · secondary NCT02082210
  • 2.9 n 15 · Phase 1/2 · secondary NCT02082210
  • 11.0 n 25 · Phase 1 · secondary NCT02789345
OS, median—Not reported10.5 vs 9.1+1.4 vs placebon 628NCT01168973
6 other results
ORR16.7%b375 mg · n 12NCT0308304122.9% vs 13.6%+9.3 vs placebon 628NCT01168973
9 other results
Duration of response, median—Not reported12.9 vs 5.6vs Standard of Care (Inv. Choice)n 15NCT03971474
4 other results

PFS, median

Apatinib
—Not reported
Ramucirumab
4.5 vs 3+1.5 vs placebon 628NCT01168973
15 other results
  • 5.2 vs 4.2 n 76 · Phase 2 · primary NCT01703091
  • 7.2 vs 5.6 n 69 · Phase 2 · primary NCT01160744
  • 5.6 vs 5.6 n 71 · Phase 2 · primary NCT01160744
  • 8.2 n 7 · Phase 2 · primary NCT02730247
  • 4.5 vs 5.2 n 69 · Phase 2 · secondary NCT03971474
  • 1.6 abemaciclib (dose not specified) + 1250 mg/m^2 gemcitabine · n 24 · Phase 1 · secondary NCT02079636
  • 5.5 abemaciclib (dose not specified) + 500 mg/m^2 pemetrexed · n 23 · Phase 1 · secondary NCT02079636
  • 1.9 abemaciclib (dose not specified) + 100, 150, or 200 mg LY3023414 · n 36 · Phase 1 · secondary NCT02079636
  • 4.1 100 or 150 mg abemaciclib + 200 mg pembrolizumab · n 20 · Phase 1 · secondary NCT02079636
  • 4.8 abemaciclib (dose not specified) + 8 or 10 mg/kg ramucirumab on Day 1/8 · n 39 · Phase 1 · secondary NCT02079636
  • 7.8 n 40 · Phase 2 · secondary NCT00735696
  • 1.6 n 16 · Phase 1/2 · secondary NCT02082210
  • 5.4 n 45 · Phase 1/2 · secondary NCT02082210
  • 2.9 n 15 · Phase 1/2 · secondary NCT02082210
  • 11.0 n 25 · Phase 1 · secondary NCT02789345

OS, median

Apatinib
—Not reported
Ramucirumab
10.5 vs 9.1+1.4 vs placebon 628NCT01168973
6 other results

ORR

Apatinib
16.7%b375 mg · n 12NCT03083041
Ramucirumab
22.9% vs 13.6%+9.3 vs placebon 628NCT01168973
9 other results

Duration of response, median

Apatinib
—Not reported
Ramucirumab
12.9 vs 5.6vs Standard of Care (Inv. Choice)n 15NCT03971474
4 other results
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Apatinib: 4 of 5 rows · Ramucirumab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricApatinibRamucirumab
ORR
responder rate · % of participants
No placebo or comparator arm
16.7% (n=12)375 mga,b
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
55% (n=40)a,b
NCT00735696 · Phase 2 · registry result, not featured evidence · combination
4 other source trials
6.3% (n=16)
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
6.7% (n=45)
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
0% (n=15)
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
76% (n=25)
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Dropout rate
91.7%375 mgc
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
—250 mg
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
97.6%d
NCT01168973 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 28 more results
n/a: no completion milestone
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02730247 · Phase 2 · registry result, not featured evidence · combination
5.6%Ram + Gem + Carb or Cis (Squamous)
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
7.2%Ram + Pem + Carb or Cis (Non-Squam
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
—
NCT01703091 · Phase 2 · registry result, not featured evidence · combination
4.9%
NCT00735696 · Phase 2 · registry result, not featured evidence · combination
18.8%Part B - Gastric
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
13.3%Part B - HCC
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
20%Part B - RCC
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
100%Arm A: Ramucirumab + Osimertinib
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
77.3%Cohort A: Ramucirumab + Osimertini
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
13.3%200 mg abemaciclib + 500 mg/m^2 pemetrexed
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
57.1%200 mg abemaciclib + 1250 mg/m^2 gemcitabine
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
—200 mg abemaciclib + 10 mg/kg ramucirumab on Day 1
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
31.6%200 mg abemaciclib + 10 mg/kg ramucirumab on Day 1
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
33.3%200 mg abemaciclib + 150 mg LY3023414
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
—150 mg abemaciclib + 500 mg/m^2 pemetrexed
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
0%150 mg abemaciclib + 1250 mg/m^2 gemcitabine
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
—150 mg abemaciclib + 1250 mg/m^2 gemcitabine
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
—150 mg abemaciclib + 10 mg/kg ramucirumab on Day 1
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
25%150 mg abemaciclib + 10 mg/kg ramucirumab on Days 1 and 8
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
8.3%150 mg abemaciclib + 8 mg/kg ramucirumab on Days 1 and 8
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
33.3%150 mg abemaciclib + 100 mg LY3023414
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
20%150 mg abemaciclib + 150 mg LY3023414
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
37.5%150 mg abemaciclib + 200 mg LY3023414
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
29.4%150 mg abemaciclib + 200 mg pembrolizumab
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
0%100 mg abemaciclib + 100 mg LY3023414
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
0%100 mg abemaciclib + 200 mg pembrolizumab
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—375 mgc
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
—250 mg
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
15%d
NCT01168973 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 28 more results
11.6%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
—
NCT02730247 · Phase 2 · registry result, not featured evidence · combination
—Ram + Gem + Carb or Cis (Squamous)
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
—Ram + Pem + Carb or Cis (Non-Squam
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
—
NCT01703091 · Phase 2 · registry result, not featured evidence · combination
—
NCT00735696 · Phase 2 · registry result, not featured evidence · combination
—Part B - Gastric
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
—Part B - HCC
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
—Part B - RCC
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
0%Arm A: Ramucirumab + Osimertinib
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
4.5%Cohort A: Ramucirumab + Osimertini
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
6.7%200 mg abemaciclib + 500 mg/m^2 pemetrexed
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
4.8%200 mg abemaciclib + 1250 mg/m^2 gemcitabine
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
—200 mg abemaciclib + 10 mg/kg ramucirumab on Day 1
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
10.5%200 mg abemaciclib + 10 mg/kg ramucirumab on Day 1
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
0%200 mg abemaciclib + 150 mg LY3023414
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
—150 mg abemaciclib + 500 mg/m^2 pemetrexed
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
0%150 mg abemaciclib + 1250 mg/m^2 gemcitabine
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
—150 mg abemaciclib + 1250 mg/m^2 gemcitabine
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
—150 mg abemaciclib + 10 mg/kg ramucirumab on Day 1
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
0%150 mg abemaciclib + 10 mg/kg ramucirumab on Days 1 and 8
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
0%150 mg abemaciclib + 8 mg/kg ramucirumab on Days 1 and 8
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
0%150 mg abemaciclib + 100 mg LY3023414
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
0%150 mg abemaciclib + 150 mg LY3023414
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
0%150 mg abemaciclib + 200 mg LY3023414
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
0%150 mg abemaciclib + 200 mg pembrolizumab
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
0%100 mg abemaciclib + 100 mg LY3023414
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
0%100 mg abemaciclib + 200 mg pembrolizumab
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
58.3%375 mgc
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
56.6%250 mg
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
45.3%d
NCT01168973 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 28 more results
40.6%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
100%
NCT02730247 · Phase 2 · registry result, not featured evidence · combination
54.9%Ram + Gem + Carb or Cis (Squamous)
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
65.7%Ram + Pem + Carb or Cis (Non-Squam
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
31.9%
NCT01703091 · Phase 2 · registry result, not featured evidence · combination
47.5%
NCT00735696 · Phase 2 · registry result, not featured evidence · combination
25%Part B - Gastric
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
42.2%Part B - HCC
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part B - RCC
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Arm A: Ramucirumab + Osimertinib
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
36.4%Cohort A: Ramucirumab + Osimertini
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
53.3%200 mg abemaciclib + 500 mg/m^2 pemetrexed
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
47.6%200 mg abemaciclib + 1250 mg/m^2 gemcitabine
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
63.2%200 mg abemaciclib + 10 mg/kg ramucirumab on Day 1
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
—200 mg abemaciclib + 10 mg/kg ramucirumab on Day 1
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
0%200 mg abemaciclib + 150 mg LY3023414
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
50%150 mg abemaciclib + 500 mg/m^2 pemetrexed
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
—150 mg abemaciclib + 1250 mg/m^2 gemcitabine
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
33.3%150 mg abemaciclib + 1250 mg/m^2 gemcitabine
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
75%150 mg abemaciclib + 10 mg/kg ramucirumab on Day 1
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
75%150 mg abemaciclib + 10 mg/kg ramucirumab on Days 1 and 8
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
25%150 mg abemaciclib + 8 mg/kg ramucirumab on Days 1 and 8
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
22.2%150 mg abemaciclib + 100 mg LY3023414
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
30%150 mg abemaciclib + 150 mg LY3023414
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
50%150 mg abemaciclib + 200 mg LY3023414
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
52.9%150 mg abemaciclib + 200 mg pembrolizumab
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
33.3%100 mg abemaciclib + 100 mg LY3023414
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
0%100 mg abemaciclib + 200 mg pembrolizumab
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
375 mgc
rash 91.7%
hypertension 83.3%
decreased appetite 75%
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
250 mg
hypertension 63.6%
proteinuria 63.1%
aspartate aminotransferase increased 53.5%
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
d
fatigue 45.8% (placebo 42.1%)
neutropenia 36.4% (placebo 30.4%)
diarrhoea 31.9% (placebo 28.3%)
NCT01168973 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 26 more results
fatigue 56.5%
hypoalbuminemia 44.9%
hyponatremia 39.1%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
anemia 85.7%
hyponatremia 85.7%
fatigue 71.4%
NCT02730247 · Phase 2 · registry result, not featured evidence · combination
neutropenia 73.2%
fatigue 54.9%
anaemia 53.5%
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
fatigue 65.7%
nausea 52.2%
anaemia 47.8%
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
neutrophil count decreased 77.7% (placebo 70.4%)
white blood cell count decreased 77.7% (placebo 69.4%)
alopecia 67% (placebo 62.2%)
NCT01703091 · Phase 2 · registry result, not featured evidence · combination
fatigue 72.5%
neuropathy peripheral 67.5%
alopecia 57.5%
NCT00735696 · Phase 2 · registry result, not featured evidence · combination
fatigue 68.8%
decreased appetite 50%
nausea 50%
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
oedema peripheral 57.8%
fatigue 55.6%
hypoalbuminaemia 28.9%
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
dyspnoea 53.3%
fatigue 40%
menorrhagia 33.3%
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
cough 100%
diarrhoea 100%
arthralgia 66.7%
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
diarrhoea 63.6%
hypertension 63.6%
decreased appetite 40.9%
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
200 mg abemaciclib + 500 mg/m^2 pemetrexed
diarrhoea 93.3%
anaemia 80%
fatigue 80%
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
200 mg abemaciclib + 1250 mg/m^2 gemcitabine
fatigue 81%
diarrhoea 61.9%
nausea 61.9%
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
200 mg abemaciclib + 10 mg/kg ramucirumab on Day 1
diarrhoea 73.7%
fatigue 63.2%
nausea 63.2%
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
200 mg abemaciclib + 150 mg LY3023414
nausea 50%
decreased appetite 33.3%
fatigue 33.3%
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
150 mg abemaciclib + 500 mg/m^2 pemetrexed
anaemia 75%
blood creatinine increased 62.5%
fatigue 62.5%
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
150 mg abemaciclib + 1250 mg/m^2 gemcitabine
nausea 100%
anxiety 66.7%
dry skin 66.7%
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
150 mg abemaciclib + 10 mg/kg ramucirumab on Day 1
diarrhoea 50%
fatigue 50%
alanine aminotransferase increased 25%
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
150 mg abemaciclib + 10 mg/kg ramucirumab on Days 1 and 8
asthenia 75%
decreased appetite 75%
diarrhoea 50%
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
150 mg abemaciclib + 8 mg/kg ramucirumab on Days 1 and 8
diarrhoea 83.3%
decreased appetite 50%
nausea 50%
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
150 mg abemaciclib + 100 mg LY3023414
diarrhoea 66.7%
nausea 55.6%
fatigue 44.4%
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
150 mg abemaciclib + 150 mg LY3023414
diarrhoea 90%
vomiting 70%
nausea 60%
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
150 mg abemaciclib + 200 mg LY3023414
diarrhoea 75%
vomiting 75%
decreased appetite 62.5%
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
150 mg abemaciclib + 200 mg pembrolizumab
fatigue 70.6%
diarrhoea 58.8%
decreased appetite 52.9%
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
100 mg abemaciclib + 100 mg LY3023414
anaemia 66.7%
diarrhoea 66.7%
fatigue 66.7%
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
100 mg abemaciclib + 200 mg pembrolizumab
fatigue 100%
anaemia 66.7%
proteinuria 66.7%
NCT02079636 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bThe assessment timepoint is not available for both results.
  3. cPopulation comparability has not been reviewed for these studies.
  4. dPopulation comparability has not been reviewed for 28 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ramucirumab

Overall Survival 10.5 vs 9.1 placebo months
time to event · months
NCT01168973 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 4 more results
14.5 vs 11.6 Standard of Care (Inv. Choice) months
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
13.9 vs 10.4 Pem + Carb or Cis months
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
10.4 vs 10.4 Pem + Carb or Cis months
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
15.15 vs 14.65 placebo months
NCT01703091 · Phase 2 · registry result, not featured evidence · combination
PFS 4.5 vs 3 placebo months
time to event · months
NCT01168973 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 4 more results
4.5 vs 5.2 Standard of Care (Inv. Choice) months
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
7.2 vs 5.6 Pem + Carb or Cis months
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
5.6 vs 5.6 Pem + Carb or Cis months
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
5.22 vs 4.21 placebo months
NCT01703091 · Phase 2 · registry result, not featured evidence · combination
ORR 22.9% (n=628) vs 13.6% (n=625) placebo
responder rate · % of participants
NCT01168973 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 4 more results
22% (n=69) vs 28% (n=67) Standard of Care (Inv. Choice)
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
49.3% (n=69) vs 38% (n=71) Pem + Carb or Cis
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
46.5% (n=71) vs 38% (n=71) Pem + Carb or Cis
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
28.9% (n=76) vs 18.5% (n=81) placebo
NCT01703091 · Phase 2 · registry result, not featured evidence · combination
Disease Control 64% (n=628) vs 52.6% (n=625) placebo
responder rate · % of participants
NCT01168973 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 4 more results
75% (n=69) vs 73% (n=67) Standard of Care (Inv. Choice)
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
85.5% (n=69) vs 70.4% (n=71) Pem + Carb or Cis
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
73.2% (n=71) vs 70.4% (n=71) Pem + Carb or Cis
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
78.9% (n=76) vs 70.4% (n=81) placebo
NCT01703091 · Phase 2 · registry result, not featured evidence · combination
LCSS Max Improvement -5.2 vs -6.4 placebo mm
absolute value · mm
Total LCSS (n=446, 446)
NCT01168973 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
EQ-5D -0.14 vs -0.126 placebo score
absolute change · score
Health State Index Score (n=266, 272)
NCT01168973 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
EQ-5D VAS -5.9 vs -6.1 placebo score
absolute change · score
Health State VAS Score (n=272, 254)
NCT01168973 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Duration of Response 12.9 vs 5.6 Standard of Care (Inv. Choice) months
time to event · months
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
5.5 vs 4.5 Pem + Carb or Cis months
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
4.3 vs 4.5 Pem + Carb or Cis months
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
PFS 1.58 monthsabemaciclib (dose not specified) + 1250 mg/m^2 gemcitabine
time to event · months
No placebo or comparator arm
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
show 10 more results
5.55 monthsabemaciclib (dose not specified) + 500 mg/m^2 pemetrexed
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
1.87 monthsabemaciclib (dose not specified) + 100, 150, or 200 mg LY3023414
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
4.11 months100 or 150 mg abemaciclib + 200 mg pembrolizumab
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
4.83 monthsabemaciclib (dose not specified) + 8 or 10 mg/kg ramucirumab on Day 1/8
NCT02079636 · Phase 1 · registry result, not featured evidence · combination
8.16 months
NCT02730247 · Phase 2 · registry result, not featured evidence · combination
7.85 months
NCT00735696 · Phase 2 · registry result, not featured evidence · combination
1.64 months
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
5.42 months
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
2.92 months
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
11.04 months
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Stable Disease 67.7% (n=6)
event count · % of participants
No placebo or comparator arm
Best Response - Stable Disease
NCT02730247 · Phase 2 · registry result, not featured evidence · combination
Overall Survival 7.42 months
time to event · months
No placebo or comparator arm
NCT02730247 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
16.85 months
NCT00735696 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
EQ-5D Index -0.024 vs -0.007 placebo score @ 3wk
absolute change · score
Cycle 1 (n = 69, 77)
NCT01703091 · Phase 2 · registry result, not featured evidence · combination

+ 18 further endpoints in the CSV export.

Hepatocellular Carcinoma

Shared mechanism: VEGFR2 · full Hepatocellular Carcinoma pipeline

Apatinib

Marketed by Jiangsu Hengrui Pharmaceuticals under a licence from Advenchen Laboratories

Phase 3 in Hepatocellular Carcinomasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06454578 (registry estimate)

No aligned efficacy figure on record for this race.

Ramucirumab

Marketed by Eli Lilly

Approved in Hepatocellular Carcinomamonoclonal antibody
Partial signal

NCT02435433 · Phase 3 · completed

The main comparison randomized 292 participants (197 ramucirumab and 95 placebo) and was double-blind and placebo-controlled, with overall survival as the primary clinical endpoint; overall survival favored ramucirumab and met statistical significance (p=0.0199). The record enrolled 399 participants overall, including additional open-label cohorts, but no primary-endpoint power calculation is reported in the available sources, so the evidence is considered moderate rather than strong.

Reported efficacy

Overall Survival (OS) (From Date of Randomization to Death from Any Cause (Up to 28 Months)): Overall Survival (OS) (From Date of Randomization to Death from Any Cause (Up to 28 Months)): Ramucirumab + Best Supportive Care (BSC) 8.51 Months (95% CI 7 to 10.58) | Placebo + BSC 7.29 Months (95% CI 5.42 to 9.07) (met)

Result source: NCT02435433

Results for Hepatocellular Carcinoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Apatinib: registry results are on file for Hepatocellular Carcinoma, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ramucirumab

ORR 6.3% (n=16)
responder rate · % of participants
No placebo or comparator arm
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
6.7% (n=45)
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
0% (n=15)
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
Disease Control 50% (n=16)
responder rate · % of participants
No placebo or comparator arm
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
60% (n=45)
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
46.7% (n=15)
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
PFS 1.64 months
time to event · months
No placebo or comparator arm
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
5.42 months
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
2.92 months
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
Available safety results

Ramucirumab

Dropout rate
18.8%Part B - Gastric
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
13.3%Part B - HCC
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
20%Part B - RCC
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
—Part B - Gastric
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
—Part B - HCC
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
—Part B - RCC
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
25%Part B - Gastric
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
42.2%Part B - HCC
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part B - RCC
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
fatigue 68.8%
decreased appetite 50%
nausea 50%
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
oedema peripheral 57.8%
fatigue 55.6%
hypoalbuminaemia 28.9%
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination
dyspnoea 53.3%
fatigue 40%
menorrhagia 33.3%
NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Apatinib's landscape · Ramucirumab's landscape